Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 outpatient combination therapy with or without famotidine
ACTRN12622000386730Phase 2Completed
- Sponsor
- AProf Dr Karin Ried
- Start
- Apr 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ivermectin, doxycycline, ascorbic acid, vitamin d, Zinmax and 1 more in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by AProf Dr Karin Ried. Primary endpoint: Hospital admission. Started Apr 2022; status: completed.
02
Drugs
ivermectindoxycyclineascorbic acidvitamin dZinmax
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12622000386730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000386730.